Impel Pharmaceuticals
As of the edition of 20 October 2026, Impel Pharmaceuticals runs 3 drugs, 1 of them marketed; it is on route A at 5 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Impel Pharmaceuticals was bankrupt in 2024.
- Impel Pharmaceuticals: bankrupt in 2024
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dihydroergotamine | none listed | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 5 targets, route B at 0 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Impel Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 3 trials led
- Mental health: 2 trials led